CROI 2016 Program at a Glance

Keyword Index

Efavirenz - 429, 433, 441, 444, 446, 458, 470, 862, 945, 963 EFdA - 98 Effectiveness - 121, 1055 Effector/memory - 254, 299 Efficacy – 469LB, 495, 810, 818, 1120 Efficacy and safety - 472 Efficiency - 945 EFV - 40, 101 EFV400 - 1050 eGFR - 693, 857 Electronic adherence monitoring - 1029 Elimination - 1044 ELISA 4th generation - 522 Emtricitabine - 104, 107, 449, 866 End-stage liver disease - 11, 150 End-stage renal disease - 688 Endothelial dysfunction - 653, 654 Endothelium - 663 Engagement in care - 996, 1008, 1009 Entry inhibition - 97, 505 Env - 398, 505 Envelope - 33, 303, 307, 398, 505, 602 Eomes - 254 Epidemic classification - 1046 Epidemiology - 51, 52, 64, 174, 216, 526, 536, 541, 583, 590, 616, 624, 736, 890, 905, 915, 974, 1036, 1060 Epigenetics - 294, 463, 725, 851 Elite controller - 19, 190 Elvitegravir - 431, 480 Emergency department - 532

False-recent rate - 540 Family environment - 931 FDG-PET/CT - 343, 344

Global - 174, 1060 Global Hepatitis Outbreak and Surveillance

Technology (GHOST) - 149 Glucose metabolism - 711

Female reproductive tract - 268, 284, 285 Female sex workers - 226, 912, 973, 1047, 1059 Fertility desire - 864 Feasibility - 970 Fetal - 36 FGF-23 - 651 FibroScan - 606 Fibrosis - 273, 298, 528, 551 Financial incentives - 1038 First-line ART failure - 476, 482 Fisherfolk – 903, 954, 986 Fixed-dose combination - 963 Flagellin - 239 Flow cytometry - 253, 411 Fluconazole prophylaxis - 159, 760, 761 Fungal infection - 764 Fusion inhibitors - 97 –G– Gag - 137, 195, 197, 314, 465 Galectin-9 - 81 Gastric cancer - 635 Gastrointestinal - 236 GBV-C - 326 Gender - 416, 744, 918 Gender Disparities - 416, 476, 531, 1015 Gene editing - 78 Gene editing - 358LB Gene expression - 251, 324, 880 Food insecurity - 935 Fracture - 46, 698, 699 Frailty - 709, 719, 723 Functionality - 720

Glutaminase - 397 Glycosylation - 81 Gonorrhea - 922, 1005 gp120 - 181, 724 gp160 trimer - 138

gp41 motif - 304 Group sex - 926 Growth - 852, 858 Guidelines - 643, 832, 869 Guinea - 75LB Gut associated lymphoid tissue (GALT) - 233, 238, 348, 450 Gut homing - 274, 289 Gut immunology - 187, 235, 237, 262

Gut microbiome - 261, 262, 657 Gut microbiota - 21, 260, 266 GWAS - 601 –H– HAART - 589, 707, 724, 959, 1039 Hair concentrations - 866 Haiti - 473, HAND - 144, 146, 388, 389, 406, 420 Harm reduction - 533 HAV/HBV responsiveness - 329 HBsAg - 570 Health care providers - 892, 966 Health district - 910

Epithelial cells - 235, 725 Epitope - 152, 303, 313 Epstein-Barr virus - 630, 780 Eradication - 25, 353 ERAP - 667 ERCHIVES - 581 ESRD - 432 Europe - 486, 630, 1044 EWAS - 851 Ex vivo - 245LB, 285 Executive function - 390 Exercise - 719 Exhaustion - 269, 596, 826 Exosomes - 250, 559 Explant - 874

Helicobacter pylori - 635 Heme oxygenase-1 - 394

Hemodialysis - 432 Hepatitis - 124, 591 Hepatitis BVirus (HBV) - 150, 562, 563, 566, 567, 571, 607, 804 Hepatitis BVirus (HBV)-HIV co-infection – 567 Hepatitis C virus (HCV) - 11, 64, 149, 150, 329, 525, 526, 527, 532, 533, 534, 535, 537, 539LB, 540, 542, 543, 544, 546, 549, 551, 554, 556, 557, 575, 577, 578, 579, 595, 597, 600, 606, 607, 608, 611, 639, 693, 804 • Continuum of care – 587 • Genotype 6 - 606 • HIV coinfection – 9, 100, 329, 413, 527, 541, 545, 550, 556, 559, 573, 574, 575, 582, 584, 605, 610 • Incidence - 64, 544, 546

Gene therapy - 78, 356, 357 Genetic diversity - 226, 959 Genetic polymorphism - 247 Genetic polymorphisms - 444, 445 Genetic variant - 149, 780 Genital tract of women - 102LB Genital tract sampling - 439, 987 Genome - 20 Genome-wide association - 499 Genomics - 737 Genotype - 525 Geographic differences - 214 Geographic origin - 943 Germinal center - 233, 334 GHESKIO - 750, 1017 Genetics - 17 Genital - 284

Exposure-Response - 425 Extended Duration - 98 ExtracellularVesicles - 397 –F– Falls - 720 False-positive diagnoses - 516, 786

• Inhibitors - 525 • NS5A - 578, 579

Keyword Index CROI 2016 168